Cryo-Save Group NV: Purchase Shares Chairman

Cryo-Save Group NV: Purchase Shares Chairman

ID: 55842

(Thomson Reuters ONE) -


Cryo-Save Group N.V. (Euronext: CRYO, 'Cryo-Save', or 'the Group'), the leading
international family stem cell bank, has been informed that Mr Johan Goossens,
Chairman, purchased 10,000 ordinary shares of Euro 0.10 ('Ordinary Shares') at a
price of ?4.95 on 23 June 2011.

Following this purchase, the receipt of the dividend in shares and a transfer as
part of Mr. Goossens estate planning, he is now beneficially interested in
1,290,003 ordinary shares, representing approximately 13.9% of the Group's
issued share capital.

Enquiries:

Cryo-Save Group + 31 (0) 575 548 998

Arnoud van Tulder, Chief Executive Officer



SPJ Financiële Communicatie (The Netherlands) +31 (0)20 647 8181

Kees Jongsma/Leon Melens


Daniel Stewart & Company plc (UK) + 44 (0) 20 7776 6550

Sean Lunn



College Hill (UK) + 44 (0) 20 7457 2020

Rozi Morris/ Adrian Duffield



Free footage is available on www.videobankonline.com

About Cryo-Save (www.cryo-save.com/group)

Cryo-Save, the leading international family stem cell bank, already stores
175,000 samples from cord blood and umbilical cord tissue for newborns and
adipose tissue for adults. These stem cells can mean the difference between life
and death in the case of future threats to the health of the donors. There are
already several diseases that can be cured by the use of stem cells, and the
number of treatments will only increase. Driven by its international business
strategy, Cryo-Save is now represented in 40 countries on three continents, with
ultra-modern processing and storage facilities in Belgium, Germany, Dubai, India
and France (validation in progress).





Click here for press release in PDF:




http://hugin.info/143308/R/1525905/461707.pdf




This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.

Source: Cryo-Save Group N.V. via Thomson Reuters ONE

[HUG#1525905]


Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  Estimated Net Asset Value(s) Novartis drug Votubia® recommended by CHMP for approval in the EU for children and adults with SEGA associated with tuberous sclerosis
Bereitgestellt von Benutzer: hugin
Datum: 24.06.2011 - 09:55 Uhr
Sprache: Deutsch
News-ID 55842
Anzahl Zeichen: 2662

contact information:
Town:

Zutphen



Kategorie:

Business News



Diese Pressemitteilung wurde bisher 140 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Cryo-Save Group NV: Purchase Shares Chairman"
steht unter der journalistisch-redaktionellen Verantwortung von

Cryo-Save Group N.V. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Cryo-Save Group N.V.



 

Werbung



Sponsoren

foodir.org The food directory für Deutschland
News zu Snacks finden Sie auf Snackeo.
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z